Next |
home / stock / crvs / crvs message board
Subject | By | Source | When |
---|---|---|---|
Price now | masterofdisaster | investorshub | 05/16/2023 8:15:50 AM |
$CRVS short squeeze | BooDog | investorshub | 05/16/2023 3:50:49 AM |
$CRVS Good read | masterofdisaster | investorshub | 05/15/2023 2:21:46 PM |
$CRVS Price now last trade up | gene_genome | investorshub | 05/14/2023 11:20:05 PM |
$CRVS MomentumIts now up | masterofdisaster | investorshub | 05/14/2023 3:57:31 PM |
$CRVS Good read | kenyonn2000 | investorshub | 05/10/2023 4:48:55 AM |
bears and bulls | BooDog | investorshub | 05/09/2023 8:00:51 PM |
$CRVS The now up | kenyonn2000 | investorshub | 05/09/2023 7:58:43 PM |
short squeeze | diversified holdings | investorshub | 05/09/2023 12:53:55 PM |
MomentumIts now last up | DaDaWin | investorshub | 05/07/2023 11:23:56 PM |
got some short data | Roadtojourney | investorshub | 05/06/2023 10:48:56 PM |
short data if anyone is interested | flatlander_60048 | investorshub | 05/05/2023 10:54:46 PM |
$CRVS The now | kenyonn2000 | investorshub | 05/04/2023 10:51:39 PM |
$CRVS Have a look at this | kenyonn2000 | investorshub | 05/04/2023 4:13:30 PM |
must see | gene_genome | investorshub | 04/30/2023 4:34:42 PM |
$CRVS The gaining | flatlander_60048 | investorshub | 04/29/2023 11:55:06 AM |
$CRVS in Compliance w Nasdaq requirements. | flatlander_60048 | investorshub | 04/24/2023 7:14:04 PM |
$CRVS The now | kenyonn2000 | investorshub | 04/22/2023 11:44:29 AM |
The now last trade up | flatlander_60048 | investorshub | 04/21/2023 9:41:23 PM |
$CRVS The now last up | MyBio | investorshub | 04/21/2023 12:11:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE...
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potentia...
BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, ...